摘要
目的 评估为期１２周的安里申５ｍｇ治疗轻至中度阿尔茨海默病（ＡＤ）的安全性与有效性。方法 根据严格的诊断标准与病例入选与排除标准，选择ＭＭＳＥ１１～ ２４分的轻至中度的ＡＤ病例，进行５ｍｇ安里申每晚一次的治疗，持续１２周。应用ＭＭＳＥ，ＣＤＲ，ＡＤＬ评估疗效，并观察任何不良反应的发生。结果 病例总数为６５例，经１２周治疗后，症状有明显改善者共８例（１２．３１％）；症状改善者３４例（５２．３１％）；症状无变化者１８例（２７．６９％）；症状继续进展加重者５例（７．６９％）。除１例有持续３天的恶心与胃纳差外，其余病例均未发生任何不良反应。结论 为期１２周的５ｍｇ安里申治疗其对症治疗有效率为６４．６２％，未见重大不良反应。安里申每日５ｍｇ为安全而具有一定疗效的ＡＤ对症治疗药物。
Objective Clinical evaluation of efficacy and safety of a 12-week course of Aricept 5mg/day in the treatment of mild to moderate Alzheimer disease. Methods Adopting international diagnostic criteria of Alzheimer disease, with strict inclusion and exclusion criteria, cases with MMSE score 11 - 24 were selected for the trial. MMSE, CDR and ADL were used for efficacy assessment. Side-effects during the treatment course were recorded, with evaluation and follow-up. Results 65 cases were selected for treatment. 8 cases (12. 31 % ) were markedly improved, 34 cases (52 .31 % ) had improvements, 18 cases (27. 69% ) had no change, and 5 cases (7. 69 % ) worsened. Besides transient nausea and decrease of appetite lasting 3 days in 1 case, no other side-effects were observed in the remaining 64 cases. Conclusions Aricept is an effective and safe drug for the symptomatic treatment of Alzheimer disease.
出处
《老年医学与保健》
CAS
2000年第3期129-131,共3页
Geriatrics & Health Care
关键词
安里申
临床评估
早老性痴呆
Aricept(Donepezil)
Alzheimer disease
Clinical evaluation
